This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -7.14% and -92.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Smith & Wesson, Zscaler, Sportsman's Warehouse, ProQR and Ooma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Wesson, Zscaler, Sportsman's Warehouse, ProQR and Ooma
5 Must-Buy Low-Beta Stocks Flying High in a Volatile Market
by Nalak Das
At this stage, we have narrowed down our search to five low-beta stocks that have provided double-digit returns in the past month.
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
by Zacks Equity Research
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
5 Low-Beta Stocks to Beat Renewed Coronavirus Concerns
by Nilanjan Banerjee
To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.
How ProQR (PRQR) Stock Stands Out in a Strong Industry
by Zacks Equity Research
ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 23.91% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Editas, Allergan Start Dosing in Early-Stage Eye Disease Study
by Zacks Equity Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study
by Zacks Equity Research
ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.
Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
by Zacks Equity Research
Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -9.38% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
Will ProQR Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor ProQR Therapeutics.
ProQR Therapeutics Enters Oversold Territory
by Zacks Equity Research
ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
by Zacks Equity Research
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
by Zacks Equity Research
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 24.44% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -13.89% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
by Zacks Equity Research
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.